- Home
- ESPR vs ATXS Comparison
ESPR vs ATXS Comparison
Compare ESPR & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- ATXS
- Stock Information
- Founded
- ESPR 2008
- ATXS 2008
- Country
- ESPR United States
- ATXS United States
- Employees
- ESPR N/A
- ATXS N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- ATXS Health Care
- Exchange
- ESPR Nasdaq
- ATXS Nasdaq
- Market Cap
- ESPR 445.6M
- ATXS 424.4M
- IPO Year
- ESPR 2013
- ATXS 2015
- Fundamental
- Price
- ESPR $2.76
- ATXS $7.60
- Analyst Decision
- ESPR Buy
- ATXS Buy
- Analyst Count
- ESPR 6
- ATXS 6
- Target Price
- ESPR $6.50
- ATXS $33.00
- AVG Volume (30 Days)
- ESPR 6.0M
- ATXS 337.6K
- Earning Date
- ESPR 11-06-2025
- ATXS 11-12-2025
- Dividend Yield
- ESPR N/A
- ATXS N/A
- EPS Growth
- ESPR N/A
- ATXS N/A
- EPS
- ESPR N/A
- ATXS N/A
- Revenue
- ESPR $268,125,000.00
- ATXS N/A
- Revenue This Year
- ESPR $9.87
- ATXS N/A
- Revenue Next Year
- ESPR N/A
- ATXS N/A
- P/E Ratio
- ESPR N/A
- ATXS N/A
- Revenue Growth
- ESPR N/A
- ATXS N/A
- 52 Week Low
- ESPR $0.69
- ATXS $3.56
- 52 Week High
- ESPR $3.94
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- ESPR 71.69
- ATXS 57.24
- Support Level
- ESPR $2.69
- ATXS $6.99
- Resistance Level
- ESPR $2.85
- ATXS $7.94
- Average True Range (ATR)
- ESPR 0.17
- ATXS 0.51
- MACD
- ESPR -0.00
- ATXS 0.02
- Stochastic Oscillator
- ESPR 82.72
- ATXS 70.46
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.